In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
no speaker photo
Speaker
Alberico Catapano
Alberico Catapano Alberico Catapano

University of Milan, Milan (Italy)

Speciality : Pharmacology and Pharmacotherapy

Alberico Catapano is Full Professor of Pharmacology and Director of the Center of Epidemiology and Preventive Pharmacology at the University of Milan, as well as Director of the Laboratory of Lipoproteins, Immunity and Atherosclerosis and the Center for the Study of Atherosclerosis at Bassini Hospital, and at Multimedica IRCCS Milan, Italy. His main research interests include the study of atherosclerosis, lipids, lipoproteins and genetic dyslipidaemias, and he has made landmark observations regarding heat shock proteins and pentraxins in atherogenesis, on high-density lipoproteins in the modulation of the immune response, and on the identification of possible therapeutic targets by exploiting genetic information. A past President of the European Atherosclerosis Society (EAS), Professor Catapano is currently Co-Chairman of the EAS/European Society of Cardiology (ESC) guidelines for the treatment of dyslipoproteinaemias, President of the Italian Society of Clinical and Experimental Thera

44 presentations from this speaker

Panel Discussion.

Event : ESC Congress 2020

  • Session : Managing patients with dyslipidaemia: how to tackle clinical inertia
  • Speaker : A Catapano (Milan,IT), JW Jukema (Leiden,NL), L Masana (Reus,ES), F Mach (Geneva,CH)
  • Sponsored by Sanofi

Summary and conclusions.

Event : ESC Congress 2020

  • Session : Managing patients with dyslipidaemia: how to tackle clinical inertia
  • Speaker : A Catapano (Milan,IT)
  • Sponsored by Sanofi

Welcome and introductions.

Event : ESC Congress 2020

  • Session : Managing patients with dyslipidaemia: how to tackle clinical inertia
  • Speaker : JW Jukema (Leiden,NL), A Catapano (Milan,IT)
  • Sponsored by Sanofi

2019 ESC/EAS Guidelines on Dyslipidaemias.

Event : ESC Congress 2019

  • Session : 2019 ESC Guidelines Overview
  • Speaker : C Baigent (Bicester,GB), A Catapano (Milan,IT)

Do we still care about triglycerides?

Event : ESC Congress 2019

  • Session : Evolving concepts in lipidology
  • Speaker : A Catapano (Milan,IT)

Formulating appropriate lipid-lowering treatment goals and strategies.

Event : ESC Congress 2019

  • Session : 2019 ESC/EAS Guidelines on Dyslipidaemias
  • Speaker : A Catapano (Milan,IT)

How to apply the new ESC Dyslipidemias Guidelines?

Event : ESC Congress 2019

  • Session : Novel ESC Guidelines 2019 – Clinical cases put into practice
  • Speaker : A Catapano (Milan,IT)

Latest insights into cholesterol management - Interactive questions and answers discussion

Event : ESC Congress 2019

  • Session : Latest insights into cholesterol management for the post-myocardial infarction patient
  • Speaker : F Mach (Geneva,CH), A Catapano (Milan,IT), D Atar (Oslo,NO)
  • Sponsored by MSD

On the horizon - Emerging targets for lipid-lowering drugs

Event : ESC Congress 2019

  • Session : Beyond statins - Evolving concepts for the management of dyslipidaemia
  • Speaker : A Catapano (Milan,IT)
  • Daiichi Sankyo Europe Gmbh

Putting the updated ESC/EAS guidelines in to practice - Expert panel discussion

Event : ESC Congress 2019

  • Session : A deep dive in to guidelines - Combination therapy, a cornerstone in CV risk reduction
  • Speaker : A Catapano (Milan,IT), Z Reiner (Zagreb,HR), U Landmesser (Berlin,DE), R Santos (Sao Paulo,BR), M Farnier (Fixin,FR)
  • Sponsored by Sanofi-Aventis Groupe

Summary and audience questions and answers

Event : ESC Congress 2019

  • Session : A deep dive in to guidelines - Combination therapy, a cornerstone in CV risk reduction
  • Speaker : A Catapano (Milan,IT), Z Reiner (Zagreb,HR), U Landmesser (Berlin,DE), R Santos (Sao Paulo,BR), M Farnier (Fixin,FR)
  • Sponsored by Sanofi-Aventis Groupe

What we have learned from the Familial Hypercholesterolemia Study Collaboration

Event : ESC Congress 2019

  • Session : Latest insights into cholesterol management for the post-myocardial infarction patient
  • Speaker : A Catapano (Milan,IT)
  • Sponsored by MSD

Emerging evidence-based approaches to reduce residual atherosclerotic risk - ask the experts.

Event : ESC Congress 2018

  • Session : Emerging evidence-based approaches to reduce residual atherosclerotic risk - Ask the experts
  • Speaker : PM Ridker (Boston,US), A Catapano (Milan,IT)
  • Sponsored by Novartis Pharma AG

From guidelines to real life practices in lipid management: how to empower patients for better treatment adherence.

Event : ESC Congress 2018

  • Session : From guidelines to real life practices in lipid management: how to empower patients for better treatment adherence
  • Speaker : A Catapano (Milan,IT), G Reach (Bobigny,FR)
  • Sponsored by Sanofi and Regeneron

New aspects of the patho-biology of atherosclerosis: the role of lipids and inflammation.

Event : ESC Congress 2018

  • Session : LDL goals and inflammation. From basic science to clinical practice.
  • Speaker : A Catapano (Milan,IT)

Next steps in addressing HDL cholesterol clinical practice.

Event : ESC Congress 2018

  • Session : HDL cholesterol - A moving target
  • Speaker : A Catapano (Milan,IT)

Concluding remarks - PSCK9 inhibition: a new horizon in LDL-C management.

Event : ESC Congress 2017

  • Session : PSCK9 inhibition: a new horizon in LDL-C management
  • Speaker : A Catapano (Milan,IT)
  • Sponsored by Sanofi and Regeneron

Identifying appropriate patients to treat: a case-based approach.

Event : ESC Congress 2017

  • Session : PSCK9 inhibition: a new horizon in LDL-C management
  • Speaker : C Cannon (Boston,US), A Catapano (Milan,IT), SJ Nicholls (Adelaide,AU), PM Ridker (Boston,US), J Robinson (Iowa,US)
  • Sponsored by Sanofi and Regeneron

Inflammation plays a key role in coronary artery disease - CON

Event : ESC Congress 2017

  • Session : Inflammation and cardiovascular disease
  • Speaker : A Catapano (Milan,IT)

Inflammation plays a key role in coronary artery disease - Rebuttal CON

Event : ESC Congress 2017

  • Session : Inflammation and cardiovascular disease
  • Speaker : A Catapano (Milan,IT)

Introduction - PSCK9 inhibition: a new horizon in LDL-C management.

Event : ESC Congress 2017

  • Session : PSCK9 inhibition: a new horizon in LDL-C management
  • Speaker : A Catapano (Milan,IT), J Robinson (Iowa,US), C Cannon (Boston,US)
  • Sponsored by Sanofi and Regeneron

LDL-C exposure and atherosclerosis progression.

Event : ESC Congress 2017

  • Session : PSCK9 inhibition: a new horizon in LDL-C management
  • Speaker : A Catapano (Milan,IT)
  • Sponsored by Sanofi and Regeneron

Lipid-lowering therapy in primary prevention: where will we be 10 years from now

Event : ESC Congress 2017

  • Session : Cholesterol-lowering therapy for primary and secondary prevention
  • Speaker : A Catapano (Milan,IT)

Panel discussion - PSCK9 inhibition: a new horizon in LDL-C management.

Event : ESC Congress 2017

  • Session : PSCK9 inhibition: a new horizon in LDL-C management
  • Speaker : C Cannon (Boston,US), A Catapano (Milan,IT), J Robinson (Iowa,US)
  • Sponsored by Sanofi and Regeneron

Resolving inflammation in atherosclerosis: the role of lipoproteins

Event : ESC Congress 2017

  • Session : Reducing the danger from atherosclerotic plaque
  • Speaker : A Catapano (Milan,IT)
  • Joint with the European Atherosclerosis Society

Dyslipidaemias - Part 2

Event : ESC Congress 2016

  • Session : ESC Guidelines 2016 - Overview
  • Speaker : A Catapano (Milan,IT)

Dyslipidaemias.

Event : ESC Congress 2016

  • Session : Meet the Guidelines Task Force - Dyslipidaemias
  • Speaker : A Catapano (Milan,IT)

Future challenges

Event : ESC Congress 2016

  • Session : The new dyslipidaemias Guidelines
  • Speaker : A Catapano (Milan,IT)

Lipid target: the lower the better?

Event : ESC Congress 2016

  • Session : 2016 European Guidelines on cardiovascular disease prevention in clinical practice.
  • Speaker : A Catapano (Milan,IT)

Lipids: what is new?

Event : Heart Failure 2016

  • Session : The new European Guidelines on CVD Prevention 2016. Be the first to know!
  • Speaker : A Catapano (Milan,IT)

PCSK9 inhibitors: redefining clinical practice.

Event : ESC Congress 2016

  • Session : PCSK9 inhibitors: redefining clinical practice
  • Speaker : A Catapano (Milan,IT), J Kastelein (Amsterdam,NL), KK Ray (London,GB), J Robinson (Iowa,US)
  • Sponsored by Sanofi and Regeneron

Pentraxins - Experimental and clinical relevance in cardiovascular disease

Event : ESC Congress 2016

  • Session : Innate immunity in cardiovascular disease
  • Speaker : A Catapano (Milan,IT)

Targeting PCSK9 for hypercholesterolemia.

Event : Frontiers in CardioVascular Biology 2016

  • Session : New approaches in lipid-lowering therapy: from molecular medicine to therapeutic opportunities
  • Speaker : A Catapano (Milan,IT)
  • This session is supported by Unrestricted Educational Grants from AMGEN and Sanofi

The 2016 ESC Guidelines and EAS Guidelines on Dyslipidemia – Highlights.

Event : ESC Congress 2016

  • Session : The clinical trial update in blood cholesterol management 2016
  • Speaker : A Catapano (Milan,IT)
  • Sponsored by MSD

Conclusion - A consensus on atherogenic dyslipidaemia.

Event : ESC Congress 2015

  • Session : A consensus on atherogenic dyslipidaemia
  • Speaker : A Catapano (Milan,IT)
  • Sponsored by MYLAN

Future direction for research in low-density lipoprotein lowering.

Event : ESC Congress 2015

  • Session : Low-density lipoprotein cholesterol: how low and how to lower?
  • Speaker : A Catapano (Milan,IT)

PCSK9 inhibitors: are they the new statins?

Event : ESC Congress 2015

  • Session : What is beyond statins in dyslipidaemia treatment?
  • Speaker : A Catapano (Milan,IT)
  • ESC and the European Atherosclerosis Society

Targeting LDL-c: commonalities and differences among major guidelines.

Event : ESC Congress 2015

  • Session : Targeting the high-risk patient: evolving concepts on optimally modifying risk by lipid-modulating therapies
  • Speaker : A Catapano (Milan,IT)
  • Organised by Leiden University Medical Center Course Director: Wouter Jukema Supported by an unrestricted educational grant from AstraZeneca

Chair welcome and opening remarks - LDL-C & cardiovascular disease.

Event : ESC Congress 2014

  • Session : LDL-C & cardiovascular disease - What are the critical questions and what is the evidence?
  • Speaker : A Catapano (Milan,IT)
  • Sponsored by MSD

Management of dyslipidemia: European perspective and new horizons.

Event : ESC Congress 2014

  • Session : Risk factor reduction in CAD - do we require different strategies in developing countries?
  • Speaker : A Catapano (Milan,IT)

The importance of lowering LDL-C: a European perspective.

Event : ESC Congress 2014

  • Session : Comparing the European and US (ACC/AHA) lipid lowering therapy guidelines: the good, the bad and the uncertain
  • Speaker : A Catapano (Milan,IT)
  • Organised by University Hospital, Umea / Course Director: Ulf Naeslund / Supported by an unrestricted educational grant from AstraZeneca

Monoclonal antibodies: from discovery to clinical application.

Event : ESC Congress 2013

  • Session : Changing paradigms in lipid drug discovery: the emerging role of genomics and biotechnology
  • Speaker : A Catapano (Milan,IT)
  • Sponsored by Sanofi and Regeneron

Panel discussion: changing paradigms in lipid drug discovery.

Event : ESC Congress 2013

  • Session : Changing paradigms in lipid drug discovery: the emerging role of genomics and biotechnology
  • Speaker : C Ballantyne (Houston,US), GK Hovingh (Amsterdam,NL), A Catapano (Milan,IT)
  • Sponsored by Sanofi and Regeneron

PCSK9 (proprotein convertase subtilisin/kexin type 9) from biology to clinical applications.

Event : ESC Congress 2013

  • Session : Hot topics in dyslipidemias and cardiovascular disease
  • Speaker : A Catapano (Milan,IT)

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are